|Bid||52.47 x 1800|
|Ask||52.48 x 2200|
|Day's range||51.13 - 52.70|
|52-week range||38.48 - 61.71|
|Beta (5Y monthly)||0.71|
|PE ratio (TTM)||12.03|
|Earnings date||26 Jul 2022 - 01 Aug 2022|
|Forward dividend & yield||1.60 (3.16%)|
|Ex-dividend date||12 May 2022|
|1y target est||59.33|
Shares of Pfizer (NYSE: PFE) were up 2.5% as of 11:35 a.m. ET on Friday after jumping as much as 4% earlier in the day. Meanwhile, the stocks of two other COVID-19 vaccine makers were declining. Moderna's (NASDAQ: MRNA) shares were down 4.7%.
Pfizer and Merck managed to gain solid upside momentum despite broad market pullback.
FDA grants emergency approval to Pfizer's COVID-19 vaccine for use in children 5- to 11-year old and approves Lilly's (LLY) novel diabetes treatment, Mounjaro (tirzepatide).